122 related articles for article (PubMed ID: 6274363)
1. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
Vilageliu J; Freixes J; Giráldez A; Bermejo P; Basi N; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1805-7. PubMed ID: 6274363
[TBL] [Abstract][Full Text] [Related]
2. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
Bruseghini L; Vilageliu J; Freixes J
Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
[TBL] [Abstract][Full Text] [Related]
3. Hypolipemic activity of plafibride.
Bruseghini L; Vilageliu J; Bagaria A
Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity.
Ribalta JM; Artús JJ; Salvador L; Roma E; Vilageliu J; Freixes J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1782-6. PubMed ID: 6797442
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic approach of plafibride in rat.
Zapatero D; Vilageliu J; Torres A; Ribalta JM; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1800-4. PubMed ID: 7198457
[TBL] [Abstract][Full Text] [Related]
6. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
Palmieri B; Gasparini Casari M; DiBlasio P; Zirilli E
Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
[TBL] [Abstract][Full Text] [Related]
7. Plafibride tolerance trial in healthy volunteers.
Dalmau J; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials of plafibride in geriatric patients.
Demichelis Genesio MA; Bracons R; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of plafibride in healthy volunteers.
Santaniello E; Conti F; Vilageliu J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
[TBL] [Abstract][Full Text] [Related]
10. Plafibride tolerance trial at increasing doses in healthy volunteers.
Dalmau J; Vicens B; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
[TBL] [Abstract][Full Text] [Related]
11. Activity of plafibride on erythrocyte deformability.
Vilageliu J; Freixes J; Bruseghini L
Arzneimittelforschung; 1983; 33(3):401-4. PubMed ID: 6683514
[TBL] [Abstract][Full Text] [Related]
12. Toxicological studies of plafibride. Part 4: Interaction of plafibride with other drugs.
Zapatero J; Basi N; Vilageliu J; Sanfeliu C; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1835-8. PubMed ID: 7198461
[TBL] [Abstract][Full Text] [Related]
13. Plafibride: clinical trial of a new platelet antiaggregating agent.
Olivella J; Vicens B
Arzneimittelforschung; 1981; 31(10a):1856-8. PubMed ID: 7032532
[TBL] [Abstract][Full Text] [Related]
14. Favorable effects of the lipid-lowering and platelet antiaggregant Plafibride on the aging process of mice of the C57bl/6J strain.
Calatayud JM
Methods Find Exp Clin Pharmacol; 1983 Dec; 5(10):707-14. PubMed ID: 6672489
[TBL] [Abstract][Full Text] [Related]
15. Toxicological studies of plafibride. Part 2: Subacute and subchronic toxicity in rats and chronic toxicity in dogs.
Zapatero J; Sanfeliu C; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1819-30. PubMed ID: 7198459
[TBL] [Abstract][Full Text] [Related]
16. Toxicological studies of plafibride. Part 1: Acute toxicity and its determination after several administrations of plafibride.
Zapatero J; Sanfeliu C; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1816-9. PubMed ID: 7198458
[TBL] [Abstract][Full Text] [Related]
17. Bacterial mutation test on plafibride.
Richold M; Jones E
Arzneimittelforschung; 1981; 31(10a):1838-40. PubMed ID: 7032531
[TBL] [Abstract][Full Text] [Related]
18. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
Badimón JJ; Padró T; Cánovas M; Vidal M; Villaverde CA
Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of antiplatelet activity of PC-09, a newly synthesized pyridazinone derivative.
Cherng SC; Huang WH; Shiau CY; Lee AR; Chou TC
Eur J Pharmacol; 2006 Feb; 532(1-2):32-7. PubMed ID: 16457809
[TBL] [Abstract][Full Text] [Related]
20. Toxicological studies of plafibride. Part 3: Study of teratogenic activity in rats and rabbits.
Sanfeliu C; Zapatero J; Bruseghini L
Arzneimittelforschung; 1981; 31(10a):1831-4. PubMed ID: 7198460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
